Table 8

VRK2 as prognostic index in astrocytomas
Risk group No. patients % Hazard ratio (95% C.I.) Median survival (months) (95% C.I.) Pvalue Survival rate
1-year 2-year 3-year
Low-risk 28 (37.8%) 1 15.7 (12.3 – 19.0) <0.001 67.9% 25.5% 21.3%
High-risk 46 (62.2%) 2.64 (1.53 – 4.55) 9.8 (7.9 – 11.8) 39.8% 7.0% 0.0%

Rodríguez-Hernández et al.

Rodríguez-Hernández et al. BMC Clinical Pathology 2013 13:23   doi:10.1186/1472-6890-13-23

Open Data